AOHA Stock Chart & Stats
€0.28
€0.01(4.03%)
At close: 4:00 PM EDT
€0.28
€0.01(4.03%)
Day’s Range― - ―
52-Week Range€0.09 - €0.35
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.75M
Enterprise Value€6.08
Total Cash (Recent Filing)€3.25M
Total Debt (Recent Filing)€794.00K
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Jul 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Biomaterials PlatformThe company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.
Revenue Scale And Gross MarginRevenue has expanded substantially over the reported period while gross margin remains strong, indicating that the business can retain meaningful value from its specialized products and services. If maintained, this gross-profit base provides capacity to fund development and move toward operating profitability.
Conservative Balance SheetLow leverage and a substantial equity base provide financial flexibility relative to a highly indebted structure. This should reduce interest and refinancing pressure, preserve room for investment in biomaterials programs, and improve resilience while the company works toward stable earnings.
Bears Say
Operating Losses PersistOperating profitability has not yet been established, so strong gross margin is not currently translating into sustainable earnings after operating costs. Continued EBIT losses could restrict internal funding, delay shareholder returns, and leave results sensitive to the timing of customer-program progress.
Negative Cash GenerationThe business remains cash-consuming rather than self-funding, even though annual burn has improved materially from earlier periods. Persistent negative operating and free cash flow can increase reliance on external capital and constrain the pace of product development or manufacturing expansion.
Returns Remain UnsettledSlightly negative return on equity and a modest net loss show that the company is not yet generating dependable returns on its capital base. Until earnings stabilize, the healthy balance sheet may support continuity but cannot by itself demonstrate an attractive or durable economic return.
RUA Life Sciences News
AOHA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest stock price was €0.09 and its highest was €0.35 in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is €20.75M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 19, 2027 which is in 288 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jun 30, 2026. The company reported -€0.004 earnings per share for the quarter.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went up 0.602%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in DE:AOHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―